Pliant reported Q3 2025 net loss of $26.3 million compared to $57.8 million in Q3 20241
Research and development expenses decreased to $17.9 million from $47.8 million year-over-year, largely due to discontinuation of the BEACON-IPF trial12
Cash, cash equivalents, and short-term investments totaled $243.3 million as of September 30, 202512
General and administrative expenses decreased to $10.3 million from $14.3 million in the prior year1
The company completed enrollment in its Phase 1 trial for PLN-101095, its lead drug candidate for solid tumors, with data expected by end of 202512
PLRX beat earnings expectations for Q3 2025, reporting an EPS of -$0.43 versus analyst estimate of -$0.534
BEACON-IPF Phase 2b/3 trial close-out activities are expected to be completed in Q4 20251
The company completed a voluntary prepayment of its outstanding loan with Oxford Finance LLC2
Sources:
1. https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-eb251vyy477n.html
2. https://www.tipranks.com/news/company-announcements/pliant-therapeutics-reports-improved-q3-2025-results